Dietary supplements marketed for muscle building and weight loss now account for roughly one in six cases of severe liver injury tracked by the largest U.S. registry devoted to the problem. Between 2004 and 2013, the proportion of cases tied to these products climbed sharply, outpacing conventional prescription drugs in both severity and the likelihood of requiring a liver transplant. Federal regulators and disease investigators have separately linked specific bodybuilding and weight-loss products to clusters of acute hepatitis and liver failure, yet no mandatory national reporting system exists to count every case.
Supplement-linked liver damage is rising faster than drug-related cases
The NIH-funded Drug-Induced Liver Injury Network, known as DILIN, operates a prospective registry that enrolled patients at multiple U.S. medical centers from 2004 through 2013. Over that period, researchers documented a steady increase in the share of liver injuries attributed to supplements relative to conventional medications. By the registry’s later years, supplements accounted for about one in six adjudicated cases, a proportion that had roughly doubled from the registry’s early enrollment window. The pattern held even after researchers applied standardized causality scoring to rule out other explanations.
A separate DILIN cohort analysis covering hundreds of patients with liver damage established the broader framework for tracking how agents are implicated and how severity is measured. That dataset confirmed the secular trend: supplements were claiming a growing share of cases over time, and the injuries they caused tended to be more severe on average than those triggered by prescription drugs. Patients whose liver damage was linked to bodybuilding or weight-loss supplements were younger and more likely to need emergency transplantation.
One reason the trend matters beyond the registry is that DILIN captures only referral-center cases, not every instance across the country. A prospective gastroenterologist-based surveillance effort in Delaware attempted to fill that gap by estimating population-level incidence of drug- and supplement-related liver injury. The preliminary findings from that Delaware surveillance effort suggested that registry proportions likely understate how often supplements cause liver damage in the general population, because many cases never reach a specialty referral center.
Steroid-laced bodybuilding products at the center of the problem
The hypothesis that undeclared anabolic steroids or their chemical analogs drive the worst outcomes has strong support from both regulatory and clinical evidence. The FDA published an analysis documenting that bodybuilding products with steroid-like ingredients continue to cause serious liver injury. The agency flagged a recurring problem: users often take multiple products at once, which complicates efforts to pin blame on a single ingredient. That multi-product exposure pattern also makes targeted mass-spectrometry screening of individual supplements less definitive than it might seem, because the chemical culprit in a given patient’s regimen can be difficult to isolate.
CDC field investigators documented a concrete example of the damage. Between May and October 2013, a cluster of acute hepatitis and liver failure emerged among people who had used a dietary supplement intended for weight loss or muscle building. The CDC identified cases through outreach to transplant programs, a method that captured only the most severe outcomes and almost certainly missed milder injuries that resolved without hospitalization.
Clinical researchers drilled further into the mechanism. A study of young men with severe cholestasis after taking bodybuilding supplements assessed genetic, clinical, and chemical risk factors. The cholestasis in these patients was unusually prolonged, lasting weeks to months, and the researchers used lab-based inclusion criteria and standardized severity scoring to confirm the connection. Genetic and chemical analyses pointed to specific compounds in the supplements as likely triggers, reinforcing the link between steroid-containing products and lasting liver damage.
The American Association for the Study of Liver Diseases incorporated these findings into its guidance on liver injury from drugs and supplements. That document summarized the observational and registry evidence, cited the commonly referenced proportion of DILIN cases attributable to supplements, and outlined available reporting pathways such as FDA MedWatch. The guidance effectively confirmed that the clinical specialty most responsible for treating liver disease now treats supplement injuries as a routine and growing part of its caseload.
Gaps in tracking and regulation leave the full toll unknown
Several unresolved questions limit the ability to measure the true scope of the problem. The DILIN registry’s published data cover enrollment through 2013, leaving a gap in publicly available, systematically collected information about more recent trends. Because participation depends on referral to specialized centers and patient consent, the registry is not designed to yield a complete national incidence estimate. Mild and moderate cases that resolve in community settings without hospitalization are especially likely to be missed.
Regulatory reporting is similarly incomplete. Manufacturers are required to submit serious adverse event reports for dietary supplements, but consumers and clinicians are not obligated to report suspected cases, and underreporting is widely acknowledged. Voluntary submissions to systems such as MedWatch can help investigators identify clusters, but they do not provide a reliable denominator for calculating risk. When outbreaks are identified, as in the 2013 hepatitis cluster, they typically come to light through ad hoc collaborations between transplant centers, state health departments, and federal agencies rather than through a routine national surveillance mechanism.
Product variability further obscures the picture. Many bodybuilding and weight-loss supplements are marketed as proprietary blends, with incomplete or misleading ingredient lists. Laboratory testing in regulatory investigations has repeatedly found undeclared steroids, stimulants, or other pharmacologically active compounds in products sold as “natural.” Reformulations and brand name changes are common, meaning that the specific chemical exposures associated with a given label can shift over time. As a result, even careful case investigations may struggle to link a particular pattern of liver injury to a stable, identifiable agent.
Clinicians face their own diagnostic challenges. Patients may not volunteer supplement use unless specifically asked, and even when they do, recall can be incomplete. Distinguishing supplement-induced injury from viral hepatitis, autoimmune disease, or metabolic conditions requires extensive testing and, often, liver biopsy. Standardized causality assessment tools used in research settings are not always applied in routine practice, which can lead to inconsistent attribution and further undercounting of supplement-related cases in administrative data.
These gaps have policy consequences. Without robust, up-to-date estimates of incidence and risk by product category, regulators and lawmakers lack the empirical foundation to calibrate oversight. Targeted enforcement against clearly hazardous products is possible when outbreaks are documented, but proactive risk management for the broader supplement market remains difficult. Meanwhile, consumers are left with little practical guidance beyond generic warnings, even as evidence accumulates that certain categories-particularly bodybuilding and weight-loss supplements-pose disproportionate risks to the liver.
Researchers and liver disease specialists have called for several incremental steps: wider education of clinicians about the need to ask specifically about supplement use; standardized recording of suspected supplement-related liver injury in electronic health records; and stronger incentives for manufacturers and distributors to monitor and report adverse events. Some have also urged the development of a more formal national surveillance system that integrates clinical registries, regulatory reports, and laboratory findings to detect emerging hazards earlier.
For now, the available data paint a consistent, if incomplete, picture. Severe liver injury associated with dietary supplements-especially those marketed for muscle building and weight loss-has become a regular feature of hepatology practice and a recurrent concern for regulators. The rise documented in referral registries, the outbreaks traced to specific products, and the mechanistic studies of steroid-like compounds all point in the same direction. Absent more comprehensive tracking and stronger quality controls, the true burden is likely higher than current figures suggest, and the risks to consumers will remain difficult to see until they result in the most serious outcomes.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
